• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Exact Sciences Reports Q1 Loss, Joins Beyond Meat, Duolingo And Other Big Stocks Moving Lower In Thursday's Pre-Market Session

    5/9/24 5:49:11 AM ET
    $ABNB
    $ARGX
    $ARM
    $BVS
    Diversified Commercial Services
    Consumer Discretionary
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $ABNB alert in real time by email

    U.S. stock futures were lower this morning, with the Dow futures falling around 100 points on Thursday.

    Shares of Exact Sciences Corporation (NASDAQ:EXAS) fell sharply in today's pre-market trading after the company reported mixed first-quarter financial results.

    Exact Sciences said first-quarter revenue increased 6% year-over-year to $638 million, which beat the consensus estimate of $627.355 million, according to Benzinga Pro. The company reported a quarterly loss of 60 cents per share, which missed analyst estimates for a loss of 48 cents per share.

    Exact Sciences shares dipped 17.4% to $49.15 in pre-market trading.

    Here are some big stocks recording losses in today's pre-market trading session.

    • Cardlytics, Inc. (NASDAQ:CDLX) shares tumbled 28.8% to $10.40 in pre-market trading after the company reported mixed first-quarter financial results.
    • Delta Apparel, Inc. (NYSE:DLA) shares declined 23.5% to $2.15 pre-market trading following weaker-than-expected second-quarter results.
    • Bioventus Inc. (NASDAQ:BVS) shares declined 20% to $4.03 in pre-market trading. Bioventus recently reported better-than-expected first-quarter financial results and raised its FY24 guidance above estimates.
    • Beyond Meat, Inc. (NASDAQ:BYND) shares declined 13.4% to $7.11 in pre-market trading after the company reported a wider-than-expected loss for its first quarter. The company sees second-quarter revenue to be between $85 million and $90 million and full-year 2024 revenue to be between $315 million and $345 million.
    • Duolingo, Inc. (NASDAQ:DUOL) shares dipped 12.4% to $213.95 in pre-market trading after the company reported first quarter financial results.
    • SolarEdge Technologies, Inc. (NASDAQ:SEDG) shares fell 8.8% to $52.47 in pre-market trading after the company reported mixed first quarter financial results.
    • Arm Holdings plc (NASDAQ:ARM) shares fell 8.6% to $96.89 in pre-market trading after the company reported fourth-quarter financial results and issued guidance.
    • Airbnb, Inc. (NASDAQ:ABNB) shares declined 8% to $145.30 in pre-market trading following first-quarter results.
    • Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) shares dipped 7.7% to $4.95 in pre-market trading following weak quarterly results.
    • argenx SE (NASDAQ:ARGX) shares declined 7.4% to $357.60 pre-market trading after the company reported first quarter financial results and issued a business update.
    • LifeMD, Inc. (NASDAQ:LFMD) shares fell 7.1% to $11.46 in pre-market trading following first-quarter earnings.
    • Forward Air Corporation (NASDAQ:FWRD) shares declined 7.1% to $19.99 in pre-market trading following weak quarterly results.
    • HubSpot, Inc. (NYSE:HUBS) shares fell 4.4% to $564.20 in pre-market trading following soft second-quarter revenue guidance.

    Now Read This: Warner Bros. Discovery Likely To Report Narrower Q1 Loss; Here Are The Recent Forecast Changes From Wall Street’s Most Accurate Analysts

    Don't forget to check out our premarket coverage here

    Get the next $ABNB alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ABNB
    $ARGX
    $ARM
    $BVS

    CompanyDatePrice TargetRatingAnalyst
    Vanda Pharmaceuticals Inc.
    $VNDA
    3/5/2026$18.00Buy
    Truist
    Duolingo Inc.
    $DUOL
    2/27/2026$100.00Buy → Hold
    Truist
    Duolingo Inc.
    $DUOL
    2/27/2026$100.00Buy → Neutral
    BofA Securities
    Duolingo Inc.
    $DUOL
    2/27/2026$100.00Sector Outperform → Sector Perform
    Scotiabank
    Duolingo Inc.
    $DUOL
    2/27/2026$95.00Overweight → Neutral
    Analyst
    Duolingo Inc.
    $DUOL
    2/27/2026$114.00Outperform → In-line
    Evercore ISI
    Duolingo Inc.
    $DUOL
    2/27/2026$100.00Overweight → Equal-Weight
    Morgan Stanley
    Duolingo Inc.
    $DUOL
    2/27/2026$101.00Buy → Neutral
    Citigroup
    More analyst ratings

    $ABNB
    $ARGX
    $ARM
    $BVS
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Truist initiated coverage on Vanda Pharma with a new price target

    Truist initiated coverage of Vanda Pharma with a rating of Buy and set a new price target of $18.00

    3/5/26 8:32:16 AM ET
    $VNDA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Duolingo downgraded by Truist with a new price target

    Truist downgraded Duolingo from Buy to Hold and set a new price target of $100.00

    2/27/26 12:55:49 PM ET
    $DUOL
    Computer Software: Prepackaged Software
    Technology

    Duolingo downgraded by BofA Securities with a new price target

    BofA Securities downgraded Duolingo from Buy to Neutral and set a new price target of $100.00

    2/27/26 10:22:22 AM ET
    $DUOL
    Computer Software: Prepackaged Software
    Technology

    $ABNB
    $ARGX
    $ARM
    $BVS
    SEC Filings

    View All

    Beyond Meat Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

    8-K - BEYOND MEAT, INC. (0001655210) (Filer)

    3/6/26 4:32:50 PM ET
    $BYND
    Packaged Foods
    Consumer Staples

    Amendment: SEC Form SCHEDULE 13G/A filed by HubSpot Inc.

    SCHEDULE 13G/A - HUBSPOT INC (0001404655) (Subject)

    3/6/26 12:58:52 PM ET
    $HUBS
    Computer Software: Prepackaged Software
    Technology

    SEC Form 6-K filed by argenx SE

    6-K - ARGENX SE (0001697862) (Filer)

    3/6/26 6:15:09 AM ET
    $ARGX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ABNB
    $ARGX
    $ARM
    $BVS
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Shelton James H bought $498,792 worth of shares (5,000 units at $99.76), increasing direct ownership by 108% to 9,632 units (SEC Form 4)

    4 - Duolingo, Inc. (0001562088) (Issuer)

    3/4/26 4:49:44 PM ET
    $DUOL
    Computer Software: Prepackaged Software
    Technology

    Large owner Cetus Capital Vi, L.P. bought $4,034,950 worth of shares (225,000 units at $17.93) and sold $5,940,112 worth of shares (272,163 units at $21.83), decreasing direct ownership by 1% to 3,116,546 units (SEC Form 4)

    4 - FORWARD AIR CORP (0000912728) (Issuer)

    2/17/26 9:56:39 PM ET
    $FWRD
    Integrated Freight & Logistics
    Industrials

    President and CEO Polymeropoulos Mihael Hristos bought $41,500 worth of shares (10,000 units at $4.15), increasing direct ownership by 0.43% to 2,335,731 units (SEC Form 4)

    4 - Vanda Pharmaceuticals Inc. (0001347178) (Issuer)

    8/8/25 4:05:18 PM ET
    $VNDA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ABNB
    $ARGX
    $ARM
    $BVS
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    FDA Approval for PONVORY issued to VANDA PHARMS INC

    Submission status for VANDA PHARMS INC's drug PONVORY (SUPPL-6) with active ingredient PONESIMOD has changed to 'Approval' on 06/05/2024. Application Category: NDA, Application Number: 213498, Application Classification: Labeling

    6/17/24 12:07:18 AM ET
    $VNDA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FDA Approval for PONVORY issued to VANDA PHARMS INC

    Submission status for VANDA PHARMS INC's drug PONVORY (SUPPL-5) with active ingredient PONESIMOD has changed to 'Approval' on 06/05/2024. Application Category: NDA, Application Number: 213498, Application Classification: Labeling

    6/17/24 12:07:18 AM ET
    $VNDA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FDA Approval for FANAPT issued to VANDA PHARMS INC

    Submission status for VANDA PHARMS INC's drug FANAPT (SUPPL-23) with active ingredient ILOPERIDONE has changed to 'Approval' on 04/02/2024. Application Category: NDA, Application Number: 022192, Application Classification: Efficacy

    4/3/24 4:12:36 PM ET
    $VNDA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ABNB
    $ARGX
    $ARM
    $BVS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SVP & General Counsel Williams Timothy sold $350,755 worth of shares (42,434 units at $8.27), decreasing direct ownership by 10% to 377,450 units (SEC Form 4)

    4 - Vanda Pharmaceuticals Inc. (0001347178) (Issuer)

    3/4/26 6:54:11 PM ET
    $VNDA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SVP, CFO & Treasurer Moran Kevin Patrick sold $350,821 worth of shares (42,442 units at $8.27), decreasing direct ownership by 9% to 411,380 units (SEC Form 4)

    4 - Vanda Pharmaceuticals Inc. (0001347178) (Issuer)

    3/4/26 6:53:14 PM ET
    $VNDA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SVP, Chief Marketing Officer Wijkstrom Joakim sold $254,590 worth of shares (30,800 units at $8.27), decreasing direct ownership by 8% to 333,469 units (SEC Form 4)

    4 - Vanda Pharmaceuticals Inc. (0001347178) (Issuer)

    3/4/26 6:52:29 PM ET
    $VNDA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ABNB
    $ARGX
    $ARM
    $BVS
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    argenx to Present New Data at 2026 AAN Annual Meeting that Continue to Transform Patient Outcomes in MG and CIDP and Build Upon Strength of Pipeline

    Positive results from Phase 3 ADAPT OCULUS study show VYVGART's potential as the first targeted treatment for patients living with ocular MG Additional data from ADAPT SERON – the largest study of patients with gMG who do not have detectable AChR-Ab – demonstrate VYVGART's efficacy and safety across subtypesNew biomarker analysis, real-world evidence and post-hoc insights highlight VYVGART's expanding treatment approach in CIDP March 6, 2026, 7:00 AM CEST Amsterdam, the Netherlands – argenx SE ((Euronext &, NASDAQ:ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, will present data for VYVGART® (IV: efgartigimod alfa-f

    3/6/26 1:00:00 AM ET
    $ARGX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Cardlytics Announces Fourth Quarter and Full Year 2025 Financial Results

    Cardlytics, Inc. (NASDAQ:CDLX) today announced financial results for the fourth quarter and full year ended December 31, 2025. "In 2025, we took several steps to reset our business and improve our financial health," said Amit Gupta, CEO of Cardlytics. "Going forward, we remain well positioned to execute our mandate and deliver for our partners and advertisers, even as we navigate a decrease in MQUs following the conclusion of our Bank of America campaigns in January. We are moving forward with sharper focus and discipline to control our own destiny by prioritizing our initiatives that build on our core fundamental strengths." "It has been reinvigorating to rejoin the Cardlytics team," s

    3/4/26 4:02:00 PM ET
    $CDLX
    Computer Software: Programming Data Processing
    Technology

    Exact Sciences Named Gallup Exceptional Workplace Award Winner for Third Consecutive Year

    Exact Sciences Corp. (NASDAQ:EXAS), a leading provider of cancer screening and diagnostic tests, today announced it has earned the 2026 Gallup Exceptional Workplace Award (GEWA), marking the third consecutive year the company has received this prestigious recognition. The award honors organizations with some of the most engaged workplace cultures in the world. Gallup recognized Exact Sciences for fostering a culture where employees feel valued and connected to the company's mission, enabling strong performance even during periods of change and complexity. "Our people are the heart of Exact Sciences," said Sarah Condella, executive vice president of human resources. "This recognition bel

    3/4/26 9:00:00 AM ET
    $EXAS
    Medical Specialities
    Health Care

    $ABNB
    $ARGX
    $ARM
    $BVS
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by SolarEdge Technologies Inc.

    SC 13G/A - SOLAREDGE TECHNOLOGIES, INC. (0001419612) (Subject)

    11/14/24 4:38:03 PM ET
    $SEDG
    Semiconductors
    Technology

    Amendment: SEC Form SC 13G/A filed by argenx SE

    SC 13G/A - ARGENX SE (0001697862) (Subject)

    11/14/24 1:22:37 PM ET
    $ARGX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form SC 13G filed by HubSpot Inc.

    SC 13G - HUBSPOT INC (0001404655) (Subject)

    11/14/24 1:22:36 PM ET
    $HUBS
    Computer Software: Prepackaged Software
    Technology

    $ABNB
    $ARGX
    $ARM
    $BVS
    Leadership Updates

    Live Leadership Updates

    View All

    Airbnb Announces Fourth Quarter and Full Year 2025 Results

    SAN FRANCISCO, Feb. 12, 2026 /PRNewswire/ -- Airbnb, Inc. (NASDAQ:ABNB) has posted a shareholder letter containing its fourth quarter and full year 2025 financial results on its Investor Relations website at https://investors.airbnb.com. Airbnb will host an audio webcast to discuss its results at 2:00 p.m. PT / 5:00 p.m. ET today. The link to the webcast will be made available on the Investor Relations website at https://investors.airbnb.com. Interested parties can register for the call in advance by visiting https://registrations.events/direct/Q4I66365458. After registering,

    2/12/26 4:03:00 PM ET
    $ABNB
    Diversified Commercial Services
    Consumer Discretionary

    Edgewater Wireless Issues 2026 Corporate Update

    "Wi-Fi8 Before Wi-Fi8" – Accelerating Wi-Fi8-ready Spectrum Slicing™ Silicon with Silicon Catalyst Ecosystem, Arm, Synopsys and FABrIC Support Edgewater Wireless Systems Inc. (TSXV:YFI) (OTC:KPIFF), the industry pioneer of AI-powered Wi-Fi Spectrum Slicing™ silicon solutions and IP for residential, enterprise and Industrial IoT markets, today issued a corporate update outlining the Company's material progress over the past 12 months and its 2026 execution roadmap toward Wi-Fi8-ready silicon deliverables and strategic commercialization. Over the last year, Edgewater has evolved from an innovation-led Wi-Fi disruptor into a globally recognized reliability and low-latency thought leader, a

    2/5/26 7:01:00 AM ET
    $ARM
    $SNPS
    Semiconductors
    Technology
    Computer Software: Prepackaged Software

    Quanterix Appoints Everett Cunningham as President and CEO Effective January 19, 2026

    Planned Leadership Transition Positions Company for Growth Company Expects to Exceed Revenue and Cash Guidance for the Full Year 2025 Quanterix Corporation ("Quanterix" or the "Company") (NASDAQ:QTRX), a company transforming healthcare by accelerating biomarker breakthroughs from discovery to diagnostics, today announced that its Board of Directors (the "Board") has appointed Everett Cunningham as the Company's next President and Chief Executive Officer and a member of the Board, effective January 19, 2026. Mr. Cunningham will succeed Masoud Toloue, who will continue to serve as Chief Executive Officer until Mr. Cunningham assumes the role on January 19, 2026. Following Mr. Cunningham

    1/8/26 4:30:00 PM ET
    $ARVN
    $DGX
    $EXAS
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Medical Specialities
    Biotechnology: Laboratory Analytical Instruments

    $ABNB
    $ARGX
    $ARM
    $BVS
    Financials

    Live finance-specific insights

    View All

    Cardlytics Announces Fourth Quarter and Full Year 2025 Financial Results

    Cardlytics, Inc. (NASDAQ:CDLX) today announced financial results for the fourth quarter and full year ended December 31, 2025. "In 2025, we took several steps to reset our business and improve our financial health," said Amit Gupta, CEO of Cardlytics. "Going forward, we remain well positioned to execute our mandate and deliver for our partners and advertisers, even as we navigate a decrease in MQUs following the conclusion of our Bank of America campaigns in January. We are moving forward with sharper focus and discipline to control our own destiny by prioritizing our initiatives that build on our core fundamental strengths." "It has been reinvigorating to rejoin the Cardlytics team," s

    3/4/26 4:02:00 PM ET
    $CDLX
    Computer Software: Programming Data Processing
    Technology

    argenx Reports Full Year 2025 Financial Results and Provides Fourth Quarter Business Update

    $1.3 billion in fourth quarter and $4.2 billion in full year global product net sales, representing 90% year‑over‑year growth Delivered $1.1 billion in operating income in 2025, marking first year of operating profitability VYVGART MG label expansion supported by positive ADAPT SERON and OCULUS results; PDUFA target action date of May 10, 2026 for anti‑AChR antibody‑negative ("seronegative") gMG Management to host conference call today at 2:30 PM CET (8:30 AM ET) February 26, 2026 7:00 AM CET Amsterdam, the Netherlands – argenx ((Euronext &, NASDAQ:ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today reported f

    2/26/26 1:00:00 AM ET
    $ARGX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Bioventus to Report Fourth Quarter of Fiscal Year 2025 Financial Results on March 5, 2026

    DURHAM, N.C., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Bioventus Inc. (NASDAQ:BVS) ("Bioventus" or the "Company"), a global leader in innovations for active healing, today announced that it will report financial results for the fourth quarter of fiscal year 2025 before the market opens on Thursday, March 5, 2026. The Company's management will host a conference call at 8:30 a.m. Eastern Time that same day to discuss the results and provide a business update. To participate in the conference call, dial 1-833-636-0497 and refer to the Bioventus Inc. Conference Call. A live webcast of the call and accompanying materials will also be provided on the "Investor Relations" section of the Company's webs

    2/24/26 4:15:00 PM ET
    $BVS
    Medical/Dental Instruments
    Health Care